3Brain
Private Company
Total funding raised: $53.2M
Overview
Founded in 2010, 3Brain is a pioneer in merging microelectronics with biology to revolutionize in vitro electrophysiology. Its flagship CorePlate™ technology embeds a custom BioSignal Processing Unit (BioSPU) into each culture well, enabling unprecedented parallel, real-time recording and stimulation of thousands of electrodes for studying neuronal networks, brain organoids, and other electrogenic cells. With over two decades of scientific heritage, headquarters near Zürich, and operations in Italy and the US, the company aims to accelerate neuroscience research and pharmaceutical screening by providing superior spatial and temporal resolution compared to traditional methods.
Technology Platform
CorePlate™ technology integrates a custom CMOS BioSignal Processing Unit (BioSPU) into cell culture plates, creating high-density microelectrode arrays (HD-MEAs) for real-time, bidirectional, label-free electrophysiological recording and stimulation of 2D and 3D cellular networks.
Funding History
4Opportunities
Risk Factors
Competitive Landscape
3Brain competes with established MEA providers like Axion BioSystems and Multi Channel Systems MCS. Its main differentiation lies in its deep-tech CMOS integration, offering superior electrode density, real-time on-chip processing, true 3D electrode access, and scalable high-throughput formats, positioning it as a premium technology provider for high-content functional analysis.